Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: European Ewing Tumour Working Initiative of National Groups Ewing Tumour Studies 1999 (EURO-E.W.I.N.G.99)
Brief Summary: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy and kill more tumor cells. It is not yet known if combination chemotherapy is more effective with or without radiation therapy and/or surgery in treating Ewing's sarcoma.

PURPOSE: This randomized phase III trial is studying different combination chemotherapy regimens to see how well they work when given with or without peripheral stem cell transplantation, radiation therapy, and/or surgery in treating patients with Ewing's sarcoma.


Options:
A: Arm Label: No radiotherapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Cisplatin, Drug: Pemetrexed, Procedure: Therapeutic conventional surgery | Arm Label: Radiotherapy; Type: EXPERIMENTAL; Interventions: Drug: Cisplatin, Drug: Pemetrexed, Procedure: Therapeutic conventional surgery, Radiation: Radiotherapy | Intervention Type: DRUG; Name: Cisplatin; Assigned to Arm(s): No radiotherapy, Radiotherapy | Intervention Type: DRUG; Name: Pemetrexed; Assigned to Arm(s): No radiotherapy, Radiotherapy | Intervention Type: PROCEDURE; Name: Therapeutic conventional surgery; Assigned to Arm(s): No radiotherapy, Radiotherapy | Intervention Type: RADIATION; Name: Radiotherapy; Assigned to Arm(s): Radiotherapy
B: Arm Label: Part A, Group 1; Type: EXPERIMENTAL; Interventions: Drug: CNTO 136 100 mg, Drug: Placebo, Drug: Methotrexate | Arm Label: Part A, Group 2; Type: EXPERIMENTAL; Interventions: Drug: CNTO 136 100 mg, Drug: Placebo, Drug: Methotrexate | Arm Label: Part B, Group 1; Type: EXPERIMENTAL; Interventions: Drug: CNTO 136 100 mg, Drug: Placebo, Drug: Methotrexate | Arm Label: Part B, Group 2; Type: EXPERIMENTAL; Interventions: Drug: CNTO 136 100 mg, Drug: Methotrexate | Arm Label: Part B, Group 3; Type: EXPERIMENTAL; Interventions: Drug: CNTO 136 100 mg, Drug: Placebo, Drug: Methotrexate | Arm Label: Part B, Group 4; Type: EXPERIMENTAL; Interventions: Drug: CNTO 136 50 mg, Drug: Placebo, Drug: Methotrexate | Arm Label: Part B, Group 5; Type: EXPERIMENTAL; Interventions: Drug: CNTO 136 25 mg, Drug: Placebo, Drug: Methotrexate | Intervention Type: DRUG; Name: CNTO 136 100 mg; Assigned to Arm(s): Part A, Group 1, Part A, Group 2, Part B, Group 1, Part B, Group 2, Part B, Group 3 | Intervention Type: DRUG; Name: CNTO 136 50 mg; Assigned to Arm(s): Part B, Group 4 | Intervention Type: DRUG; Name: CNTO 136 25 mg; Assigned to Arm(s): Part B, Group 5 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Part A, Group 1, Part A, Group 2, Part B, Group 1, Part B, Group 3, Part B, Group 4, Part B, Group 5 | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): Part A, Group 1, Part A, Group 2, Part B, Group 1, Part B, Group 2, Part B, Group 3, Part B, Group 4, Part B, Group 5
C: Arm Label: Group 1; Type: EXPERIMENTAL; Interventions: Biological: dactinomycin, Drug: doxorubicin hydrochloride, Drug: etoposide, Drug: ifosfamide, Drug: vincristine sulfate, Procedure: conventional surgery, Radiation: radiation therapy | Arm Label: Group 2, arm I; Type: EXPERIMENTAL; Interventions: Biological: dactinomycin, Drug: doxorubicin hydrochloride, Drug: etoposide, Drug: ifosfamide, Drug: vincristine sulfate, Procedure: conventional surgery, Radiation: radiation therapy | Arm Label: Group 2, arm II; Type: EXPERIMENTAL; Interventions: Biological: dactinomycin, Drug: busulfan, Drug: doxorubicin hydrochloride, Drug: etoposide, Drug: ifosfamide, Drug: melphalan, Drug: vincristine sulfate, Procedure: autologous hematopoietic stem cell transplantation, Procedure: conventional surgery, Radiation: radiation therapy | Intervention Type: BIOLOGICAL; Name: dactinomycin; Assigned to Arm(s): Group 1, Group 2, arm I, Group 2, arm II | Intervention Type: DRUG; Name: busulfan; Assigned to Arm(s): Group 2, arm II | Intervention Type: DRUG; Name: doxorubicin hydrochloride; Assigned to Arm(s): Group 1, Group 2, arm I, Group 2, arm II | Intervention Type: DRUG; Name: etoposide; Assigned to Arm(s): Group 1, Group 2, arm I, Group 2, arm II | Intervention Type: DRUG; Name: ifosfamide; Assigned to Arm(s): Group 1, Group 2, arm I, Group 2, arm II | Intervention Type: DRUG; Name: melphalan; Assigned to Arm(s): Group 2, arm II | Intervention Type: DRUG; Name: vincristine sulfate; Assigned to Arm(s): Group 1, Group 2, arm I, Group 2, arm II | Intervention Type: PROCEDURE; Name: autologous hematopoietic stem cell transplantation; Assigned to Arm(s): Group 2, arm II | Intervention Type: PROCEDURE; Name: conventional surgery; Assigned to Arm(s): Group 1, Group 2, arm I, Group 2, arm II | Intervention Type: RADIATION; Name: radiation therapy; Assigned to Arm(s): Group 1, Group 2, arm I, Group 2, arm II
D: Arm Label: single arm with Tremelimumab; Type: EXPERIMENTAL; Interventions: Drug: Tremelimumab | Intervention Type: DRUG; Name: Tremelimumab; Assigned to Arm(s): single arm with Tremelimumab

Answer: C